FDA approves Infilbray, calling it the first drug for the neurological symptoms of type 3 Gaucher disease
The tablet is approved for adults and children weighing at least 15 kg, based on a 52-week study in 43 patients. The FDA lists serious psychiatric risks.
By Health & Safety Desk · · 2 min read
What it means for you
- The FDA approved Infilbray (venglustat) tablets on November 18 to treat the neurological symptoms of type 3 Gaucher disease, a rare inherited condition.
- The approval covers adults and children who weigh at least 15 kg, about 33 pounds. The FDA calls it the first treatment for these symptoms.
- In a 52-week study of 43 patients aged 12 and older, those taking Infilbray improved on a combined measure of coordination and thinking compared with those on enzyme replacement therapy, the agency says.
- The FDA lists serious psychiatric risks, including suicidal thoughts and behavior, and two potential risks identified in animal studies: clouding of vision in younger patients and adverse effects on fetal development.
The Food and Drug Administration on November 18 approved Infilbray, a tablet containing venglustat, to treat the neurological symptoms of type 3 Gaucher disease in adults and in children who weigh at least 15 kilograms, about 33 pounds. The agency describes it as the first treatment for those symptoms.
Type 3 Gaucher disease is a rare inherited condition: because an enzyme is deficient or faulty, the body cannot properly break down fatty substances called glucosphingolipids. According to the FDA, the substances accumulate in organs, tissues and the brain and cause a wide range of serious health problems over time. Type 3 differs from type 1 in that it also affects the brain and nervous system, bringing difficulties with balance, coordination, speech, memory and thinking that can grow worse.
How the drug works
According to the FDA, Infilbray blocks an enzyme called glucosylceramide synthase, and blocking it reduces the buildup of those substances throughout the body. The agency highlights that the drug crosses the blood-brain barrier, so it also reduces the buildup inside the brain.
this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms
What the study found
The approval rests on a randomized, double-blind study run at several centers. It enrolled 43 patients with type 3 Gaucher disease, aged 12 and older, who had already been treated with enzyme replacement therapy and had reached what the FDA calls systemic disease stabilization. For 52 weeks, one group took Infilbray by mouth once a day and the other received enzyme replacement therapy by intravenous infusion every two weeks.
Effectiveness was judged with two assessments of neurological symptoms central to daily life, including those related to ataxia, the loss of muscle control and coordination, and to cognitive function. At week 52, patients on Infilbray showed improvement on a measure that combined the two assessments, compared with patients taking enzyme replacement therapy for the disease's non-neurological effects, the FDA says. Its announcement does not give the size of the difference.
Side effects and risks
The most frequently reported side effects were digestive symptoms and effects on mood, according to the FDA. Serious psychiatric risks, including suicidal thoughts and behavior, have been reported. The FDA also names two potential risks identified in animal studies: clouding of vision in younger patients, and adverse effects on fetal development when the drug is taken during pregnancy. The agency says more information on side effects is in the drug's labeling.
Orphan drug status
Infilbray received Orphan Drug designation and Priority Review, and the approval was granted to Genzyme Corporation, a Sanofi company, the FDA says. Orphan designation is for products that prevent, diagnose or treat a rare disease or condition. Its incentives include tax credits for qualifying clinical trials, an exemption from FDA user fees and potentially seven years of market exclusivity after approval, according to the agency's page on orphan designation. Designation is a separate process from approval, and drugs for rare diseases go through the same scientific review as other drugs, the page says.
Sources
- FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease U.S. Food and Drug Administration, November 18, 2026
- Designating an Orphan Product: Drugs and Biological Products U.S. Food and Drug Administration, August 12, 2024
Researched and drafted with AI assistance, then checked against the 2 sources above in a separate fact-check on November 22, 2026. Spotted an error? Tell us.